<DOC>
	<DOC>NCT02978781</DOC>
	<brief_summary>This study is a two-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in up to 60 adult subjects with essential tremor.</brief_summary>
	<brief_title>A Study to Evaluate SAGE-217 in Subjects With Essential Tremor</brief_title>
	<detailed_description>Part A of the study is an open-label design with morning dosing of SAGE-217 for 7 days. Part B of the study is a double-blind, placebo-controlled, randomized withdrawal design with morning dosing for 7 days.</detailed_description>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<criteria>Key Subject must have a diagnosis of ET, defined as bilateral postural tremor and kinetic tremor, involving hands and forearms, that is visible and persistent and the duration is &gt;5 years prior to screening. Key Subject has presence of abnormal neurological signs other than tremor or Froment's sign. Subject has presence of known causes of enhanced physiological tremor. Subject has concurrent or recent exposure (14 days prior to admission visit) to tremorogenic drugs. Subject has had direct or indirect trauma to the nervous system within 3 months before the onset of tremor. Subject has historical or clinical evidence of tremor with psychogenic origin. Subject has convincing evidence of sudden tremor onset or evidence of stepwise deterioration of tremor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tremor</keyword>
</DOC>